BACKGROUND: Lymphovascular invasion (LVI) in colorectal cancer (CRC) is considered a strong stage-independent prognostic factor and influences decisions regarding adjuvant chemotherapy in patients with stage II tumors. However, the degree of interobserver agreement among pathologists for LVI in CRC is largely unknown. This study was undertaken to examine such interobserver variability, and we hypothesized that the use of immunohistochemical markers for vascular and lymphatic channels could improve interobserver agreement. DESIGN: Fifty cases of American Joint Committee on Cancer stage II moderately differentiated CRC from 1990 to 2005 from the pathology archives were selected; mucinous, medullary, and other recognized special subtypes were excluded. Fifty hematoxylin and eosin (H&E) slides (1 from each case) were circulated to 6 gastrointestinal pathologists, who independently assessed small and large vessel invasion. No diagnostic guidelines were given to the participating pathologists; each was instructed to apply the criteria for LVI that he or she used in daily practice. Immunohistochemistry (IHC) for D2-40 and CD31 was performed on corresponding paraffin blocks. The IHC slides were randomized, recirculated, and rescored for LVI. Results were analyzed by kappa (kappa) statistics, which correct for agreement by chance, and for percentage agreement. RESULTS: The average kappa values were determined for the H&E slides (large and small vessel), CD31 (small vessel), and D2-40 (small vessel) (Fig. 1). Agreement was fair for H&E small vessel invasion [kappa=0.28; 95% confidence interval (CI): 0.22-0.34]. The least agreement was seen in interpretation of H&E large vessel invasion (kappa=0.18; 95%CI: 0.11-0.26). Agreement was not improved by use of immunohistochemical stains: CD31 (large vessel, kappa=0.42, 95%CI: 0.20-0.63, small vessel, kappa=0.26, 95%CI: 0.10-0.42) and D2-40 (kappa=0.32, 95%CI: 0.21-0.42). CONCLUSIONS: Interobserver variability in diagnosis of LVI was substantial on H&E slides and did not improve upon use of IHC. Agreement in evaluation of large vessel invasion was only slightly higher than would be seen by chance alone. This study highlights the need for criteria in evaluation of LVI, as this assessment may impact patient prognosis and thus change the course of clinical treatment.
BACKGROUND: Lymphovascular invasion (LVI) in colorectal cancer (CRC) is considered a strong stage-independent prognostic factor and influences decisions regarding adjuvant chemotherapy in patients with stage II tumors. However, the degree of interobserver agreement among pathologists for LVI in CRC is largely unknown. This study was undertaken to examine such interobserver variability, and we hypothesized that the use of immunohistochemical markers for vascular and lymphatic channels could improve interobserver agreement. DESIGN: Fifty cases of American Joint Committee on Cancer stage II moderately differentiated CRC from 1990 to 2005 from the pathology archives were selected; mucinous, medullary, and other recognized special subtypes were excluded. Fifty hematoxylin and eosin (H&E) slides (1 from each case) were circulated to 6 gastrointestinal pathologists, who independently assessed small and large vessel invasion. No diagnostic guidelines were given to the participating pathologists; each was instructed to apply the criteria for LVI that he or she used in daily practice. Immunohistochemistry (IHC) for D2-40 and CD31 was performed on corresponding paraffin blocks. The IHC slides were randomized, recirculated, and rescored for LVI. Results were analyzed by kappa (kappa) statistics, which correct for agreement by chance, and for percentage agreement. RESULTS: The average kappa values were determined for the H&E slides (large and small vessel), CD31 (small vessel), and D2-40 (small vessel) (Fig. 1). Agreement was fair for H&E small vessel invasion [kappa=0.28; 95% confidence interval (CI): 0.22-0.34]. The least agreement was seen in interpretation of H&E large vessel invasion (kappa=0.18; 95%CI: 0.11-0.26). Agreement was not improved by use of immunohistochemical stains: CD31 (large vessel, kappa=0.42, 95%CI: 0.20-0.63, small vessel, kappa=0.26, 95%CI: 0.10-0.42) and D2-40 (kappa=0.32, 95%CI: 0.21-0.42). CONCLUSIONS: Interobserver variability in diagnosis of LVI was substantial on H&E slides and did not improve upon use of IHC. Agreement in evaluation of large vessel invasion was only slightly higher than would be seen by chance alone. This study highlights the need for criteria in evaluation of LVI, as this assessment may impact patient prognosis and thus change the course of clinical treatment.
Authors: K W Gilchrist; V E Gould; S Hirschl; J E Imbriglia; A S Patchefsky; D W Penner; J Pickren; I S Schwartz; J E Wheeler; J M Barnes; E G Mansour Journal: Hum Pathol Date: 1982-02 Impact factor: 3.466
Authors: Trustin S Domes; Patrick H D Colquhoun; Brian Taylor; Jonathan I Izawa; Andrew A House; Patrick P W Luke; Jonathan I Izawa Journal: Can J Surg Date: 2011-12 Impact factor: 2.089
Authors: Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso Journal: Pathol Oncol Res Date: 2019-02-01 Impact factor: 3.201
Authors: Sibylle Gündisch; Julia Slotta-Huspenina; Paolo Verderio; Chiara Maura Ciniselli; Sara Pizzamiglio; Christina Schott; Enken Drecoll; Christian Viertler; Kurt Zatloukal; Marcel Kap; Peter Riegman; Irene Esposito; Katja Specht; Gregor Babaryka; Martin Asslaber; Koppany Bodó; Michael den Bakker; Jan den Hollander; Falko Fend; Jens Neumann; Simone Reu; Aurel Perren; Rupert Langer; Alessandro Lugli; Ingrid Becker; Thomas Richter; Gian Kayser; Annette M May; Fatima Carneiro; José Manuel Lopes; Leslie Sobin; Heinz Höfler; Karl-Friedrich Becker Journal: Virchows Arch Date: 2014-08-02 Impact factor: 4.064
Authors: Alan P Venook; Donna Niedzwiecki; Margarita Lopatin; Xing Ye; Mark Lee; Paula N Friedman; Wendy Frankel; Kim Clark-Langone; Carl Millward; Steven Shak; Richard M Goldberg; Najjia N Mahmoud; Robert S Warren; Richard L Schilsky; Monica M Bertagnolli Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544